Vascular Liver Disorders
Previous guidelines reviewing vascular disorders of the liver focused on thrombosis of large vessels, such as the portal vein (PV) and hepatic vein (HV)
Previous guidelines reviewing vascular disorders of the liver focused on thrombosis of large vessels, such as the portal vein (PV) and hepatic vein (HV)
Transjugular Intrahepatic Portosystemic Shunt (TIPS) has been in use for more than 20 years to treat the complications of portal hypertension and TIPS have been created in thousands of patients with liver disease worldwide.
This first Practice Guidance on Reproductive Health from AASLD is intended to be a comprehensive reference on adolescents and adults with chronic liver disease.
AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.
Kenji Okumura, Abhay Dhand, Roxana Bodin, Seigo Nishida – 18 April 2022
Li Chen, Jun Dong, Qingtao Meng, Zhiyin Song – 18 April 2022
Michael Cooper, Rahul G. Krishnan, Mamatha Bhat – 18 April 2022
Martín Uriel Vázquez‐Medina, Eira Cerda‐Reyes, Alberto Galeana‐Pavón, Carlos Enrique López‐Luna, Patty Marlen Ramírez‐Portillo, Gabriela Ibañez‐Cervantes, Julián Torres‐Vázquez, Cruz Vargas‐De‐León – 18 April 2022 – Patients with pre‐existing liver diseases are considered to have an increased risk of morbidity and mortality from any type of infection, including viruses.
Vaibhav Singh, Emily Huang, Vai Pathak, Belinda B. Willard, Daniela S. Allende, Laura E. Nagy – 18 April 2022 – Receptor‐interaction protein kinase 3 (RIP3), a critical determinant of the necroptotic pathway of programmed cell death, contributes to injury in murine models of alcohol‐associated liver disease (ALD); however, the underlying mechanisms are unknown. We investigated the effect of chronic ethanol feeding on the hepatic phosphoproteome in C57BL/6 and RIP3‐deficient (Rip3−/−) mice, focusing on death receptor (DR) signaling pathways.
This guidance provides a data-supported approach to risk stratification, diagnosis, and management of patients with cirrhosis and portal hypertension (PH).